Tampa, FL– James “Jim” Utterback has been named chief executive officer of M2Gen, a wholly owned for-profit subsidiary of Moffitt Cancer Center. Utterback will begin work Dec. 7.
“I am fully confident that Jim will enable the M2Gen team to reach its full potential as we pursue long-term viability and growth opportunities,” said Dr. William S. Dalton, Moffitt’s CEO and center director.
Utterback will be responsible for developing and implementing effective growth strategies, determining commercialization opportunities, and establishing and executing pharmaceutical company-funded clinical trials. He will cultivate new and more efficient means of collecting clinical data electronically, as well as direct and raise required capital at appropriate valuations.
“We have a real opportunity at M2Gen to change the clinical trial world and bring trials and ultimately improved treatment protocols to cancer patients sooner,” Utterback said. “I like to call our world evidenced-based decision-making; our approach is to molecularly match patients to new treatments. I look forward to bringing M2Gen’s assets, our technology, our talent and our pride to produce ‘next generation’ cancer care for our clients and patients.”
Utterback has more than 25 years of experience building start-ups and organizations in health care software, products and services on three continents. Prior to joining M2Gen, he was the founder and chairman of RxcelPartners, LLC, a corporate consultant firm to CliniRx, and a global ventures adviser. He has served as president and chief executive officer at Reliance Clinical Research Services, chief executive officer at SCIREX (Premier Research) Corporation and president of the pharmaceutical division at VivoMetrics.
After graduating cum laude with a bachelor’s in psychology/economics from Washington and Lee University in 1977, Utterback graduated summa cum laude with a master’s in industrial psychology from Virginia Polytechnic Institute and State University in 1979. He has completed executive courses at the University of Virginia Darden School of Business and Harvard Business School. Utterback is a member of Pharmaceutical Research and Manufacturers of America, Drug Information Association and New York Pharma Forum.
About Moffitt Cancer Center
Located in Tampa, Florida, Moffitt Cancer Center is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.